AcquisitionOther

Day One Biopharmaceuticals acquired Mersana Therapeutics, Inc.

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Day One Biopharmaceuticals -> Mersana Therapeutics, Inc. · up to $55.25 per share (total deal value up to approximately $285 million)

Recognizing the value created by Mersana developing Emi-Le with Day One capabilities to bring more medicines to patients with high unmet need.